PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...

A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence ...

Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's MHRA for its small molecule therapeutic, ...

Fraser Murray, PhD, CEO, Pheno Therapeutics. Image Credit: Pheno Therapeutics A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to ...

First-in-human trial of PTD802 to commence following UK MHRA approval Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802. The ...

A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence ...

EDINBURGH, Scotland, January 14, 2025--(BUSINESS WIRE)--Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the ...

A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence agreement ...